Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.54 -0.89 (-1.50%)
Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
88 89 Next >
News headline image
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors. 
Via MarketBeat
Topics Intellectual Property
News headline image
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo ↗
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results. 
Via Benzinga
News headline image
How Is The Market Feeling About Bristol-Myers Squibb? ↗
 
Via Benzinga
News headline image
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade ↗
On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious ↗
Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a robust neuropsych pipeline. 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb ↗
 
Via Benzinga
News headline image
Unveiling 11 Analyst Insights On Bristol-Myers Squibb ↗
 
Via Benzinga
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
News headline image
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? ↗
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
Via Benzinga
News headline image
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript ↗
BMY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit ↗
Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis. Adjusted EPS of $1.80 beat estimates. 
Via Benzinga
News headline image
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance ↗
The pharma giant has been trading tightly in recent weeks. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
News headline image
Markets Give Back Gains As Hovering Continues ↗
Market indexes could not hold onto earlier gains this afternoon, and all closed near session lows. The moves were mild, though — as we’ve stated in this space previously, the big news the market is... 
Via Talk Markets
News headline image
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
News headline image
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy ↗
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
Via Benzinga
News headline image
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
From Bristol Myers Squibb
Via Business Wire
News headline image
What Lies In Store For Healthcare ETFs In Q3 Earnings? ↗
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
News headline image
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio ↗
EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes. 
Via Benzinga
News headline image
Why Is Evotec Stock Gaining Today? ↗
Evotec stock is up following progress in its partnership with Bristol Myers Squibb, including a $50 million payment. 
Via Benzinga
News headline image
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
News headline image
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
News headline image
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside ↗
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
Via Benzinga
News headline image
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold? ↗
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024. 
Via The Motley Fool
News headline image
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment ↗
The company could have a long path ahead to reimbursement and, ultimately, sales. 
Via Investor's Business Daily
News headline image
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12 ↗
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock. 
Via Talk Markets
News headline image
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report ↗
Perspective Therapeutics is down 13% at last check Friday. The downtrend comes as drug study results are presented to medical professionals. 
Via Benzinga
News headline image
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst ↗
The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.